Bibliographic Production

Peer Reviewed Original Data Journal Publications (Abstracts are not listed.  Reviews, books and book chapters are listed separately)

  1. Moon HM, Wisniewski T, Mertz P, DeMartini  J, Wisniewski HM. Purification of neurofilament subunits from bovine brains and studies on neurofilament assembly. Journal of Cell Biology 1981; 89:560-567.
  2. Onesti S, Wisniewski T, Post K. Clinical versus subclinical pituitary apoplexy: presentation, surgical management and outcome in 21 patients. Neurosurgery 1990; 26:980-986.
  3. Onesti S, Wisniewski T,  Post K. Pituitary apoplexy associated with a Rathke’s cleft cyst. Neurosurgery 1990; 27:644-646.
  4. Wisniewski T, Sisti M, Inhirami G, Knowles D, Powers J. Solitary intracranial plasmacytoma: immunohistochemical and molecular studies. Neurosurgery 1990; 27:826-829.
  5. Kitaguchi T, Wisniewski KE,  Maslinski S, Maslinska D, Wisniewski TM, Kim KS. Beta-protein immunoreactivity in brains of patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. Neuroscience Letters 1990, 112:155-160.
  6. Wisniewski T, Haltia M, Ghiso J, Frangione B. Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid. American Journal of Pathology 1991; 138:1077-1083.
  7. Castano EM, Wisniewski T, Frangione B. Inherited amyloids of the nervous system. Current Opinion in Neurobiology 1991; 1:448-454.
  8. Haltia M, Ghiso J, Miller D, Franione B, Wisniewski T. Gelsolin variant and β-amyloid co-occur in a case of Finnish amyloidosis and Alzheimer’s. Neurobiology of Aging 1991; 12:313-316.
  9. Wisniewski T, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer’s disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril  formation. Biochemical and Biophysical Research Communications 1991; 179:1247-1254.
  10. Constantinidis J, Wisniewski TM. The dominant form of the pigmentary orthochromatic leukodystrophy. Acta Neuropathologica 1991; 82:483-487.
  11. Wisniewski T, Haltia M, Ghiso J, Frangione B. Lewy bodies and gelsolin. Parkinson/Alzheimer Digest 1992; 1:6-8.
  12. Iwaki T, Wisniewski T, Iwaki A, Corbin E, Tomokane N, Tateishi J, Goldman JE. Accumulation of αΒ-crystallin in central nervous system glia and neurons in pathological conditions. American Journal of Pathology 1992; 140:345-356.
  13. Ghiso J, Wisniewski T, Vidal R, Rostagno A, Frangione B. Epitope mapping of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer’s disease. The Biochemical Journal 1992; 282:517-522.
  14. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone in systemic and cerebral amyloidoses. Neuroscience Letters 1992; 135:235-238.
  15. Constantinidis J, Wisniewski KE, Wisniewski TM. Senile neuronal ceroid lipofuscinosis, a report of three cases and a review of the literature. Acta Neuropathologica 1992; 83:461-468.
  16. Wisniewski T, Frangione B. Molecular biology of the Dutch variant of Alzheimer’s disease. Molecular Biology 1992; 6:75-86.
  17. Rodrigues M, Rajagopalan S, Jones K, Nirankari V, Wisniewski T, Frangione B, Gorevic P. Gelsolin immunoreactivity in corneal amyloid, macular and granular dystrophies and wound healing. American Journal of Opthalmology 1993; 115:644-652.
  18. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble β-amyloid. Biochemical Biophysical Research Communications 1993; 192:359-365.
  19. Ghiso J, Matsubara E, Koudinov A, Wisniewski T, Frangione B. Alzheimer’s amyloid β specifically binds SP40,40 (Apolipoprotein J), an inhibitor of the compli?ment membrane attack complex. The Biochemical Journal 1993; 293:27-30.
  20. Wisniewski T, Castano E, Ghiso J, Frangione B. Cerebrospinal fluid inhibits fibrillogenesis by Alzheimer’s disease peptides. Annals of Neurology 1993; 34: 631-633.
  21. Wisniewski T, Ghiso J, Frangione B. Alzheimer’s disease and soluble Aβ.  Neurobiology of Aging  1994; 15:143-152.
  22. Wisniewski T, Lalowski M., Levy E., Marques M.R.F., Frangione B.  The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer’s disease patient. Annals of Neurology 1994;  35:245-246.
  23. Kida E, Golabek A, Wisniewski T, Wisniewski K. Regional differences of Apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer’s disease brain. Neuroscience Letters 1994; 167: 73-76.
  24. Sanan DA, Weisgraber KH, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses A, Strittmatter WJ. Apolipoprotein E associates with β Amyloid peptide of Alzheimer’s Disease to form novel monfibrils: Isoform Apo E4 associates more efficiently than Apo E3. Journal of Clinical Investigation 1994; 94:860-869.
  25. Gallo G, Wisniewski T, Choi-Miura N, Ghiso J, Frangione B. Potential role of Apolipoprotein E in fibrillogenesis. American Journal of Pathology 1994; 145:1-5.
  26. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro. American Journal of Pathology 1994; 145:1030-1035.
  27. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb G, Frangione B, Ghiso J. Brain uptake of circulating apolipoprotein J and E complexed to Alzheimer’s amyloid β. Biochemical  Biophysical  Research  Communications 1994; 205:1431-1437.
  28. Wisniewski T, Morelli L, Wegiel J, Levy E, Wisniewski HM, Frangione B. The influence of apolipoprotein E isotype on Alzheimer’s disease pathology in 40 cases of Down’s syndrome. Annals of Neurology 1995; 36:137-139.    
  29. Mangone C, Castano E, Levy E, Abiusi G, Wisniewski T, Marques M, Faccio E, Gorelick P, Frangione B, Sica R. Early onset Alzheimer’s disease in a South American pedigree. Clinical, SPECT, immunohistochemical and DNA  findings. Acta  Neurologica Scandinavica 1995; 91:6-13.
  30. Ghiso J, Plant GT, Revesz T, Wisniewski T, Frangione B. Familial cerebral angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. Journal of Neurological Sciences 1995; 129: 74-7.
  31. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis of Alzheimer’s Amyloid β peptides and apolipoprotein E. Biochemical Journal 1995; 306:599-60.
  32. Golabek A, Marques MA, Lalowski M, Wisniewski T. Alzheimer’s Disease amyloid binding proteins in vitro and in normal human cerebrospinal fluid. Neuroscience Letters 1995; 191:79-82.  
  33. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer’s disease. American Journal of Pathology 1995; 147:238-244.
  34. Wisniewski T, Lalowski M, Golabek A, Frangione B. Alzheimer’s Disease: An apolipoprotein E amyloidosis? The Lancet 1995; 345: 956-958.
  35. Wisniewski T, Frangione B. Amyloidosis in Alzheimer’s disease. The Lancet 1995; 346: 441.
  36. Wisniewski T, Palha JA, Ghiso J, Frangione B. S182 protein in Alzheimer’s disease neuritic plaques. The Lancet, 1995 346:1366.    
  37. Wisniewski T, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid β 1-42 deposits do not lead to Alzheimer’s neuritic plaques in aged dogs. Biochemical Journal 1996; 313: 575-580.
  38. Article Featured on Cover: Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, Wisniewski T. Meningovascular amyloidosis associated with a novel transthyretin (TTR) missense mutation at codon 18 (TTRD18G). American Journal of Pathology 1996;148: 361-366.
  39. Wisniewski T, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R, Frangione B. HB-GAM is a cytokine present in Alzheimer’s and Down’s Syndrome Lesions. Neuroreport 1996; 7: 667-671.
  40. Baumann MH, Wisniewski T, Plant GT, Levy E, Ghiso J. Identification of C-terminal fragments of α- and β-tubulin in amyloid deposits of the familial cerebral amyloid angiopathy, British type. BiochemicalBiophysical Research Communications 1996; 219: 238-242.
  41. Baumann MH, Golabek A, Lalowski, Wisniewski T. Micropreparative gel electrophoresis of small molecular weight peptides: purification of highly insoluble amyloid peptide fragments. Analytical Biochemistry 1996, 236: 191-198.
  42. Soto C, Golabek A, Wisniewski T, Castano EM. Alzheimer’s soluble β-amyloid is conformationally modified by apolipoprotein E in vitro. Neuroreport 1996, 7: 721-725.
  43. Palha JA, Moreira P, Wisniewski T, Frangione B, Sariava MJ. Transthyretin gene in Alzheiemer’s disease patients. Neuroscience Letters 1996; 204: 212-214.
  44. Golabek A, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer’s amyloid β-peptide is dependent on β-peptide conformation. The Journal of Biological Chemistry 1996; 271: 10602-10606.
  45. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido T, Selkoe D. Sequence of deposition of heterogeneous amyloid β-peptides and apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiology of Disease 1996; 3:16-32.
  46. Vidal R, Ghiso J, Wisniewski T, Frangione B. Alzheimer’s presenilin 1 gene expression in platlets and megakaryocytes: Identification of a novel splice variant. FEBS Letters 1996; 393: 19-23.
  47. Garzuly F, Wisniewski T, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology, 47: 1562-1567, 1996.
  48. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, Wisniewski T. The “non-amyloidogenic” p3 fragment (amyloid β 17-42) is a major constituent of Down syndrome cerebellar preamyloid.  Journal of Biological Chemistry, 271: 33623-33631, 1996.
  49. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ. C for T substitution at codon 108: the first identified silent mutation in the transthyretin gene. Amyloid: International Journal of Experimental Clinical Investigation, 4:52-53, 1997.
  50. Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, Wisniewski T, Frangione B. Alzheimer’s soluble amyloid β is a normal component of human urine. FEBS Letters, 408: 105-108, 1997.
  51. Wisniewski T, Dowjat W, Permanne B, Palha J, Kumar A, Gallo G, Frangione B. Presenilin is associated with Alzheimer’s disease amyloid. American Journal of Pathology, 151: 601-610, 1997.
  52. Permanne B, Perez C, Soto C, Frangione B, Wisniewski T. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer’s disease brain supernatants. Biochem. Biophys. Res. Commun., 240: 715-720, 1997.
  53. Wisniewski T, Dowjat WK, Buxbaum JD, Khorhova O, Efthimiopoulos S, Kulczycki J, Lojkowska W, Wegiel J, Wisniewski HM, Frangione B. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer’s disease and leads to death as early as the age of 28 years. NeuroReport, 9: 217-221, 1998.
  54. K.E. Wisniewski, N.Zhong, W. Kaszmarski, A. Kaszmarski, E. Kida, W.T. Brown, K.O. Schwartz, E.S. Stenroos, A.M. Lazzarini, A.J. Rubin, W.G. Johnson, T.M. Wisniewski. Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis. Annals of Neurology, 43: 106-110, 1998.
  55. Askanas V, King Engel W, Chih-Chao Y, Alvarez R B, Lee VMY, Wisniewski T. Light and electron microscopic immunolocalization of presenilin I in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal recessive inclusion body myopathy. American Journal of Pathology, 152: 889-895, 1998.
  56. Wisniewski T, Goldman JE. αB-Crystallin is associated with intermediate filaments in astrocytoma cells. Neurochemistry Research, 23: 389-396, 1998.
  57. Wegiel J, Wisniewski HM, Izabela K, Michal T, Eulalia B, Eirene P, Jerzy K, Wieslaw D, Wisniewski T. Cell-type specific enhancement of amyloid ß deposition in a novel presenilin-1 mutation (P117L). Journal of Neuropathology and Experimental Neurology, 57: 831-838, 1998.
  58. Pomara N, Shao B, Wisniewski T, Mehta PD. Decreases in plasma Aß 1-40 levels with aging in non-demented elderly with apoE-epsilon 4 allele. Neurochemistry Research, 23: 1563-1566, 1998.
  59. Efthimiopoulos S, Floor E, Georgakopoulos A, Shior J, Cui W, Yasothornsrikul S, Hook VYH, Wisniewski T, Buee L, Robakis NK. Enrichment of Presenilin 1 peptides in neuronal large dense core and somatodendritic clathrin coated vesicles. Journal of Neurochemistry, 71: 2365-2372, 1998.
  60. Copp RP, Wisniewski T, Hentati F, Larnaout A, Hamida MB, Kayden HJ. Localization of α-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. Brain Research, 822: 80-87, 1999.
  61. Aucouturier P, Kascak RJ, Frangione B, Wisniewski T. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. Neuroscience Letters, 274(1):33 36, 1999.
  62. Dowjat WK, Wisniewski T, Efthimiopoulos S, Wisniewski HM. Inhibition of neurite outgrowth by Familial Alzheimer’s disease linked presenilin-1 mutations. Neuroscience Letters, 267: 141-144, 1999.
  63. Stoltner, SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA. Temporal accrual of complement proteins in amyloid plaques in Down syndrome with Alzheimer’s disease. American Journal of Pathology, 156: 489-499, 2000.
  64. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Kumar A, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational changes by synthetic ß-sheet breaker peptides. The Lancet, 355: 192-197, 2000.
  65. Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B. In Vivo Reversal of Amyloid ß Lesions in Rat Brain, Journal of Neuropathology and Experimental Neurology, 59: 11-17, 2000.
  66. Golabek AA, Kida E, Walus M, Perez C, Wisniewski T, Soto C. Sodium dodecyl sulpate-resistant complexes of Alzheimer’s amyloid -peptide with the N-terminal, receptor binding domain of apolipoprotein E. Biophysical Journal, 79: 1008-1015, 2000.
  67. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T. Amyloid 40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. Journal of Alzheimer’s Disease, 3: 23-30, 2001.
  68. Poeggeler, B, Miravalle,L, Zagorski M, Wisniewski T, Chyan YJ, ZhangY, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA. Melatonin reverses the pro-fibrillogenic effects of apolipoprotein E4 on the Alzheimer’s -amyloid protein. Biochemistry, 40: 14995-15001, 2001.
  69. Dowjat WK, Wisniewski H, Wisniewski T. Alzheimer’s disease presenilin-1 expression modulates the assembly of neurofilaments. Neuroscience, 103: 1-8, 2001.
  70. Kulczycki J, Bertrand E, Lojkowska W, Dowjat W, Wisniewski T, Lyxzywek-Zwierz M. Familial Alzheimer’s disease connected with a mutation in presenilin gene 1. Neurologia I Neurochirurgia Polska, 35: 213-224, 2001.
  71. Aucouturier P, Geissmann F, Saborio G, Meeker HC, Damotte D, Kascsak R, Kascsak R, Carp RI, Wisniewski T. Scrapie neuroinvasion in RAG-10/0 mice by transfer of infected splenic dendritic cells. Journal of Clinical Investigation, 108: 703-708, 2001.
  72. Wegiel J, Bobinski M, Tarnawski M, Dziewiatowski J, Popovitch E, Miller DC, Wisniewski T, Golomb J, de Leon MJ, Reisberg B. Fibrillar amyloid- affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. Acta Neuropathology 101: 585-590, 2001.
  73. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid- homologous peptide reduces Alzheimer’s disease associated pathology in transgenic mice. American Journal of Pathology, 159: 439-447, 2001.
  74. Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL, Ho L, Painetti GM, Robakis NK, Elder GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes hippocampal neurogenesis in adult mice, Neurobiology of Disease, 10: 8-19, 2002.
  75. Mori C, Spooner ET, Wisniewski KE, Wisniewski TM, Yamaguchi H, Saido TC, Li C, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal A42 accumulation in Down syndrome brain. Amyloid, 9:88-102, 2002.
  76. Wang ZH, Ji Y, Zeng B, Raksadawan N, Pastores GM, Ong E, Wisniewski T, Kolodny EH. Therapeutic effects of astrocytes expressing both tyrosine hydoxylase and brain-derived neurotrophic factor on a rat model with Parkinson’s disease. Neuroscience, 113: 629-640, 2002.
  77. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV. Transport across the blood-brain barrier and differential cerebrovascular sequestration of circulating Alzhiemer’s amyloid- peptide in aged Rhesus vs. aged Squirrel monkeys. Vascular Pharmacology, 38: 303-313, 2002.
  78. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson E, Macura SI, Borowski BJ, Jack CR. Molecular contrast enhanced magnetic resonance imaging of Alzheimer’s amyloid plaques. Neurobiology of Disease, 11: 315-329, 2002.
  79. De Leon MJ, Segal S, Tarshish C, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBarnardis J, Kerkmanand D, Qadri F, Gary A, Lesbre, Wisniewski T, Poirier J, Davies P. Longitudinal Tau levels increase in mild cognitive impairment. Neuroscience Letters, 333: 183-186, 2002.
  80. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Wen P, Efthimiopoulos S, Wisniewski T, Robakis NK. A presenilin-1 mediated -secretase activity cleaves cadherins and controls disassembly of adherens junctions. EMBO Journal, 21: 1948-1956, 2002.
  81. Wegiel J, Kuchna I, Wisniewski T, de Leon MJ, Reisberg B, Pirttila T, Kivimaki T, Lehtimaki. Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer’s disease and Down syndrome. Acta Neuropathologica, 103: 333-343, 2002.
  82. Sigurdsson E, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T. Vaccination delays the onset of prion disease in mice.  American Journal of Pathology, 161: 13-17, 2002.
  83. Wong BS, Li R, Sassoon J, Liu T, Pan T, Kang SC, Wisniewski T, Brown DR, Sy MS. Mapping the antigenicity of copper-treated cellular prion protein with the scrapie isoform. Cellular and Molecular Life Sciences, 60: 1224-1234, 2003.
  84. Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp RI, Meeker HC, Frangione B, Wisniewski T. Anti-PrP antibodies for prophylaxis following prion exposure. Neuroscience Letters, 336: 185-187, 2003.
  85. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguilnaldo G, Pappolla M, Duff K, Wisniewski T*, Turnbull DH* (*joint senior authors). Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance micro-imaging. Magnetic Resonance in Medicine, 50: 293-302, 2003.
  86. Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience, 122: 305-315, 2003.
  87. Sadowski M, Tang CY, Aguinaldo G, Carp R, Meeker HC, Wisniewski T. In vivo magnetic resonance imaging signal changes in scrapie infected mice. Neuroscience Letters, 345: 1-4, 2003.
  88. Sigurdsson EM, Brown D, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, Wisniewski T. Copper chelation delays the onset of prion disease. Journal of Biological Chemistry, 278: 46199-46202, 2003.
  89. Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, Wisniewski T, Sy MS, Wong BS. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie infected mice.  Journal of Pathology, 203: 603-608, 2004.
  90. Pan T, Li R, Kang SC, Wong BS, Wisniewski T, Sy MS. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scarpie prion. Journal of Neurochemistry, 90: 1205-1217, 2004.
  91. Wegiel J, Kuchna I, Novicki K, Dowjat K, Reisberg B, DeLeon M, Wisniewski T, Chen-Hwang MC, Hwang YW. Cell type and brain structure specific patterns of distribution of minibrain kinase in human brain. Brain Research, 1010: 69-80, 2004.
  92. Dowjat WK, Kuchna I, Wisniewski T, Wegiel J. A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (P117S): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations.  Journal of Alzheimer’s Disease, 6: 31-43, 2004
  93. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen C, Duff K, Nixon RA, Gruen RJ, Wisniewski T. Decreased hippocampal glucose metabolism correlates with neuronal loss and impaired recall in Alzheimer’s disease model mice. Journal of Neuropathology and Experimental Neurology, 63: 418-428, 2004.
  94. Sadowski M, Pankiewicz J, Scholtzova H, Li Y, Quartermain D, Duff K, Wisniewski T. Links between the pathology of Alzheimer’s disease and vascular dementia. Neurochemical Research, 29: 1251-1260, 2004.
  95. Helpern JA, Falangola MF, Dyakin VV, Lee SP, Bogart A, Estok K, Ardekani B, Duff K, Branch C, Wisniewski T, De Leon MJ, Wolf O, O’Shea J, Wegiel J, Nixon RA. Magnetic resonance imaging assessment of neuropathology in a transgenic mouse model of Alzheimer’s disease. Magnetic Resonance in Medicine, 51: 794-798, 2004.
  96. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T. Blocking the apolipoprotein E/ -amyloid interaction reduces -amyloid toxicity and decreases -amyloid load in transgenic mice. American Journal of Pathology, 165: 937-948, 2004.
  97. Sigurdsson EM, Knudsen E, Asuni A, Sage D, Goni F, Quartermain D, Frangione B, Wisniewski T. Enhanced cognition with a reduced immune response in an AD mouse model immunized with A derivatives. Journal of Neuroscience, 24: 6277-6282, 2004.
  98. Sadowski M, Pankiewicz J, Scholtzova H, Tsai J, Li Y, Carp RI, Meeker HC, Gambetti P, Debnath M, Mathis CA, Li S, Gan WB, Klunk WE, Wisniewski T. Targeting prion amyloid deposits in vivo using methoxy-X04, Journal of Neuropathology and Experimental Neurology, 63: 775-784, 2004.
  99. Pan T, Wong P, Chang B, Li C, Li R, Kang SC, Wisniewski T, Sy MS. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. Journal of Virology, 79: 934-943, 2005
  100. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Rubenstein R, Brown DR, Chabalgoity JA, Sigurdsson EM, Wisniewski T. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience, 133: 413-421, 2005.
  101. Pan T, Chang B, Wong P, Li C, Li R, Kang SC, Thompsett AR, Po T, Yin S, Barnard G, McConnell I, Brown DR, Wisniewski T, Sy MS. An aggregate specific ELISA: Detection of conformational differences between recombinant PrP protein dimers and PrPSc aggregates. Journal of Virology, 79: 12355-12364., 2005.
  102. Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M, Wisniewski T. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. European Journal of Neuroscience, 23: 2635-2647, 2006.
  103. Leal MC, Dorfman VB, Gamba GF, Frangione B, Wisniewski T, Castano EM, Sigurdsson EM, Morelli L. Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology. Journal of Neuropathology and Experimental Neurology, 65: :976-987, 2006.
  104. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Wen P, Quartermain D, Wisniewski T. Blocking the Apolipoprotein E/Amyloid- Interaction as a Potential Therapeutic Approach for Alzheimer's Disease. Proceedings of the National Academy of Science, 49: 18787-18792, 2006.
  105. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. European Journal of Neuroscience, 24: 2530-2542, 2006.
  106. Chang B, Cheng X, Yin S, Pan T, Zhang H, Wong P, Kang SC, Xiao F, Yan H, Li C, Wolfe LL, Miller MW, Wisniewski T, Greene MI, Sy MS. A blood test for prion: disease associated prion aggregates detected in the blood of infected but asymptomatic animals. Clinical and Vaccine Immunology, 14: 36-43, 2007
  107. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Xuemin Y, Flory MJ, Kim JI, Schuller-Levis GB, Levis WR, Wisniewski T, Carp RI, Kascsak RJ. CpG Oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. Journal of Leukocyte Biology, 14(1):36-43, 2007
  108. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, Wegiel J, Mehta PD, Silverman WP, Reisberg B, deLeon M, Wisniewski T, Pirttilla T, Frey H, Lehtimaki T, Kivimaki T, Visser FE, Kamphorst W, Potempska A, Bolton D, Currie JR, and Miller DL. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathologica (Berl),. 113(4):389-402, 2007
  109. Litterst C, Georgakopoulos A, Shioi J, Ghersi E, Wisniewski T, Wang R, Ludwig A, Robakis NK. Ligand binding and calcium influx induce distinct ectodomain/gamma -secretase processing pathways of EPHB2 receptor. Journal of Biological Chemistry  282(22):16155-63, 2007.
  110. Webb S, Lekishivili T, Loeschner C, Sellarajah S, Prelli F, Wisniewski T, Gilbert IM, Brown DR. Mechanistic insights into prion curing by novel anti-prion compounds. Journal of Virology, 81: 10729-10741, 2007.
  111. Li Q, Min J, Namm J, Kim EM, Ji Y, Wu H, Wisniewski T, Chang YT. Styryl based in vivo imaging agents for β-amyloid plaques. ChemBioChem, 8(14): 1679-1687, 2007. 
  112. Gambetti P,  Dong Z, Yuan J, Xiao X, Zheng M, Alsheklee A, Castellani R, Cohen M, Marder K, Harris C, Montine T, Wisniewski T, Dickson DW, Hulette CM, DeArmond  SJ, Mastrianni JA, Kong Q,  Zou WQ. A novel human prion disease with protease-sensitive prion. Annals of Neurology, 63: 697-708, 2008.
  113. Klybin I, Betts V, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Welzel A, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. Aß dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. Journal of Neuroscience, 28: 4231-4237, 2008.
  114. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D. 5-lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer’s disease. FASEB Journal, 22: 1169-1178, 2008.
  115. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Tsui WH, Sadowski M, Turnbull DH, de Leon M, Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiology of Aging, 29: 836-847, 2008.
  116. Goni F, Chabalgoity JA, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak R,           Kascsak R, Brown DR, Sigurdsson EM, Wisniewski T. High titers of mucosal            and systemic anti-PrP antibodies abrogates oral prion infection in mucosal      vaccinated mice. Neuroscience, 153: 679-686, 2008.
  117. Cercy SP, Sadowski MJ, Wisniewski T. Prominent neuroleptic sensitivity in a case of early-onset Alzheimer's disease due to Presenilin-1 G206A mutation. Cognitive and Behavioral Neurology, 21(3):190-195, 2008.
  118. Spinner DS, Cho IS, Park SY, Kim JI, Meeker HC, Ye X, LaFauci G, Kerr DJ, Flory MJ, Kim BS, Kascsak RB, Wisniewski T, Levis WR, Schuller-Levis GB, Carp RI, Park E, Kascsak RJ. Accelerated prion disease pathogenesis in the absence of Toll-like receptor 4 (TLR4) signaling. Journal of Virology, 82(21):10701-10708, 2008.
  119. Wegiel J, Dowjat K, Kaczmarski W, Kuchna I, Nowicki K, Frackowiak J, Mazur Kolecka B, Wegiel J, Silverman WP, Reisberg B, DeLeon M, Wisniewski T, Gong CX, Liu F, Adayev T, Chen-Hwang MC, Hwang YW. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathology, 116(4):391-407, 2008.
  120. H. Scholtzova, Y. Z. Wadghiri, M. Douadi, E. M. Sigurdsson, Y. Li, D. Quartermain, P. Banerjee, and T. Wisniewski. A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown            by micro-magnetic resonance imaging. Journal of Neuroscience Research, 86 (12):2784-2791, 2008.
  121. Trouche SG, Asuni A, Rouland S, Wisniewski T, Frangione B, Verdier JM, Sigurdsson EM, Mestre-Frances N. Antibody response and plasma Aβ1-40 in young Microcebus Murinus primates immunized with Aβ1-42 and its derivates. Vaccine, 27:957-964, 2009.
  122. Zhan J, Brys M, Glodzik L, Tsui W, Javier E, Wegiel J, Kuchna I, Pirraglia E, Li Y, Mosconi L, Saint Louis LA, Switalski R, De Santi S, Kim BC, Wisniewski T, Reisberg B, Bobinski M, de Leon MJ. An entorhinal cortex sulcal pattern is associated with Alzheimer's disease. Human Brain Mapping, 30: 874-882, 2009.
  123. Boutajangout A, Goni F, Knudsen E, Schreiber F, Asuni A, Quartermain D, Frangione B, Chabalgoity A, Wisniewski T, Sigurdsson EM. Diminished amyloid β burden in Tg2576 mice following a prophylactic oral immunization with a Salmonella based amyloid β derivative vaccine. Journal of Alzheimer's Disease, 18: 961-972, 2009.
  124. Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, Kascsak RJ, Wisniewski T. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiology of Disease, 34: 267-278, 2009.
  125. Mosconi,L.; Mistur,R.; Switalski,R.; Tsui,W.H.; Glodzik,L.; Li,Y.; Pirraglia,E.; De,Santi S.; Reisberg,B.; Wisniewski,T.; De Leon,M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 36(5): 811-822, 2009.
    This manuscript won the "Best Clinical Paper of 2009" award from Springer and the European Association of Nuclear Medicine.
  126. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology, Journal of Neuroscience, 29: 1846-1854, 2009.
  127. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E, Ma SY, Chauhan A, Chauhan V, Bobrowicz TW, de Leon M, Louis LA, Cohen IL, London E, Brown WT, Wisniewski T. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes, Acta Neuropathol., 119: 755-770, 2010.
  128. Zhang W, Li YS, Nardi MA, Dang S, Yang J, Li Z, Karpatkin S, Wisniewski T. Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus, Blood, 116: 2336-2344, 2010.
  129. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T. Immunomodulation Targeting Abnormal Protein Conformation Reduces Pathology in a Mouse Model of Alzheimer's Disease. PLoS ONE, 5(10): e13391, 2010.
  130. Chung E, Ji Y, Sun Y, Kascsak R, Kascsak R, Mehta P, Strittmatter SM, Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for A oligomer cognitive cognitive deficits. BMC Neuroscience, 11:130, 2010.
  131. Wegiel J, Kaczmarski W, Barua M, Kuchna I, Nowicki K, Wang KC, Wegiel J, Yang S, Frackowiak J, Mazur-Kolecka B, Silverman WP, Reisberg B, Monteiro I,  de Leon M, Wisniewski T, Dalton A, Lai F, Hwang YW, Adayev T, Liu F, Iqbal K, Iqbal IG, Gong CX. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. Journal of Neuropathology and Experimental Neurology, 70(1):36-50, 2011.
  132. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T. Blocking the apolipoprotein E/amyloid β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. Journal of Alzheimer’s Disease, 24(2):269-285, 2011.
  133. Yang J, Zaim Wadghiri Y, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, de Leon M, Wisniewski T. Detection of amyloid plaques targeted by USPIO-A1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage, 55: 1600-1609, 2011.
  134. Dang S, Hong T, Wisniewski T, Zhang W. A novel strategy of dissolution of pre-existing platelet thrombus by synergistic administration of a low concentration of bifunctional antibodies against beta3 integrin. PLoS ONE, 6(10): e27012, 2011.
  135. Chung E, Prelli F, Dealler S, Lee WS, Chang YT, Wisniewski T. Styryl-based and Tricyclic Compounds as Potential Anti-Prion Agents. PLoS ONE, 6(9): e24844, 2011       (
  136. Leal MC, Surace EI, Holgado MP, Ferrari CC Tarelli R, Pitossi F, Wisniewski T, Castano EM, Morelli L. Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: implications for cellular Aß metabolism. BBA-Molecular Cell Research, 1823(2): 227-235, 2012.
  137. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski T, Mehta PD, Pratico D, Zetterberg H, Blennow K. Cerebrospinal fluid amyloid beta levels are lower and F2-isoprostanes higher in individuals with major depressive disorder. American Journal of Psychiatry, 169(5):523-30, 2012.
  138. Wegiel J, Schanen NC, Cook EH, Sigman M, Brown WT, Kuchna I, Nowicki K, Wegiel J, Imaki H, Ma SY, Marchi E, Wierzba-Bobrowicz T, Chauhan A, Chauhan V, Cohen IL, London E, Flory M, Lach B, Wisniewski T. Differences between the patterns of developmental abnormalities in autism associated with duplications 15q11.2q13 and idiopathic autism. Journal of Neuropathology and Experiment Neurology, 71(5):382-397, 2012.
  139. Chang B, Petersen R, Wisniewski T, Rubenstein R. Influence of Mabs on PrPSc formation using in vitro and cell-free systems. PloS ONE, 7(7): e41626, 2012.
  140. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Takahashi H, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM. Alzheimer amyloid- oligomer bound to post-synaptic prion protein signals via Fyn to alter NMDA receptors, dendritic spines and seizures. Nature Neuroscience, 15(9): 1227-1235, 2012.
  141. Zhang W, Dang S, Hong T, Tang J, Fan J, Bu D, Wisniewski T. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood, 120(14): 2889-2898, 2012.
  142. Wegiel J, Frackowiak J, Kolecka BM, Schanen NC, Cook Jr EH, Sigman M, Brown WT, Kuchna I, Wegiel J, Nowicki K, Imaki H, Ma SY, Chauhan A, Chauhan V, Miller DL, Mehta PD, Cohen IL, London E, Reisberg B, de Leon MJ, Wisniewski T. Abnormal Intracellular Accumulation and Extracellular Aβ Deposition in Idiopathic and Dup 15 Autism. PLoS ONE, 7(5):e35414, 2012.
  143. Wisniewski T, Newman K, Javitt NB. Alzheimer’s disease: focus on desmosterol. Journal of Alzheimer’s Disease, 33: 881-888, 2013.
  144. Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Wang A, de Leon M, Wisniewski T. Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice using Magnetic Resonance Microimaging. PLoS ONE, 8(2):e57097, 2013.
  145. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Guther EC, Koleske J, Nygaard HB, Strittmatter SM.  Metabotropic Glutamate Receptor 5 Mediates Signaling from Alzheimer Aß Oligomer Bound to Prion Protein, Neuron, 79(5): 887-902, 2013.
  146. Ji Y, Liu M, Huo YR, Liu S, Shi Z, Liu S, Wisniewski T, Wang J. Apolipoprotein E4 frequency is increased among frontotemporal dementia and Alzheimer’s disease patients in a Chinese population. Dementia and Geriatric Cognitive Disorders, 36: 163-170, 2013.
  147. Rubenstein R, Chiu A, Chang B, Wisniewski T. Influence of CD40 on Prion Disease and the Immune Response to Recombinant PrP. Journal of Neuroimmunology, 257 (1-2): 21-27, 2013.
  148. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Yong Ma S, Azmitia EC, Banerjee P, Flory M, Cohen IL, London E, Brown TW, Hare KC, Wisniewski T. Contribution of olivo-floccular circuitry developmental defects to atypical gaze in autism. Brain Research, 1512: 106-122, 2013.
  149. Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta P, Wisniewski T. Immunomodulation Targeting Both Aβ and Tau Pathological Conformers Ameliorates Alzheimer’s Disease Pathology in TgSwDI and 3xTg Mouse Models. Journal of Neuroinflammation, 10: 150, 2013.
  150. Liu S, Breitbart A, Sun Y,  Mehta PD, Boutajangout A, Scholtzova H, Wisniewski T. Blocking the Apolipoprotein E/Amyloid β Interaction in Triple Transgenic Mice Ameliorates Alzheimer’s Disease Related Amyloid β and Tau Pathology. Journal of Neurochemistry, 128: 577-591, 2014.
  151. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloskavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (including Wisniewski T) Two phase 3 trials of bapineuzumab in mild to moderate Alzheimer’s disease. New England Journal of Medicine, 370(4): 322-333, 2014.
  152. Iulita MF, Carmo SD, Ower A, Fortress A, Aguilar LF, Hanna M, Wisniewski T,  Granholm AC, Buhusi M, Busciglio J, Cuello AC. Nerve Growth Factor Metabolic Dysfunction in Down’s Syndrome Brains: a Cause for Cholinergic Degeneration? Brain, 137: 860-872, 2014.
  153. Wegiel J, Flory M, Kuchna I, Nowicki K, Ma SY, Imaki H, Wegiel J, Cohen IL, London E, Wisniewski T, Brown WT. Stereological study of the neuronal number and volume of 38 brain subdivisions of subjects diagnosed with autism reveals significant alterations restricted to the striatum, amygdala and cerebellum.
    Acta Neuropathologica Communications, 2: 141, 2014.
  154. Wegiel J, Flory M, Kuchna I, Nowicki N, Ma SY, Imaki H, Wegiel J, Cohen IL, London E, Brown WT, Wisniewski T. Brain-region-specific alterations of the trajectories of neuronal volume growth throughout the lifespan in autism. Acta Neuropathologica Communications, 2: 28, 2014.
  155. Zhang Y, Shi Z, Liu M, Liu S, Yue W, Liu S, Xiang L, Lu H, Liu P, Wisniewski T, Wang J, Ji Y. Prevalence of cognitive impairment no dementia in a rural area of northern China. Neuroepidemiology, 42: 197-203, 2014.
  156. Scholtzova H, Chianchiano P, Pan J, Sun Y, Goni F, Mehta PD, Wisniewski T. Toll-like receptor 9 stimulation for reduction of amyloid β and tau Alzheimer’s disease related pathology. Acta Neuropathologica Communications, 2: 101, 2014.
  157. Wegiel J, Flory M, Kuchna I, Nowicki K, Ma SY, Imaki H, Wegiel J, Frackowiak J,  Kolecka BM, Wierzba-Bobrowicz T, London E, Wisniewski T, Brown WT. Neuronal nucleus and cytoplasm volume deficit in autistic children and volume increase in autistic adolescents and adults. Acta Neuropathologica Communications, 3(1): 2, 2015.
  158. Goñi F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A, Peyser D, Estevez V, Xu J, Osborn DA, Miller KV, Warren RJ, Brown DR, Chabalgoity JA,
    Hoover EA, Wisniewski T. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine, 33: 726-733, 2015.
  159. Chung K, Boutajangout A, Wisniewski T, Chan J, Stopler T, Vincent N, Batchan M, D’Urso J, Lin Y, Kline R, Kamer A, Stone E, Yaghmoor F, Blanck T, Quartermain D, Bekker A, Haile M. The COX-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice After Splenectomy. PLoS ONE, under review.
  160. Teohb CL, Sua D, Sahua S, Yunb SW, Prelli F, Wisniewski T , Chang YT. A Chemical Fluorescent Probe for the Detection of Aβ Oligomers. Journal of the American Chemical Society, under review.
  161. Drummond ES, Nayak S, Ueberheide B, Wisniewski T. Proteomic analysis of individual neurons isolated from formalin-fixed paraffin-embedded brain sections using laser microdissection. Nature Methods, under review

Books, Chapters in Books, Letters and Reviews:

  1. Post K, Onesti S, Wisniewski T. Pituitary Apoplexy. In Intracranial Hemorrhages: Etiology, Pathogenesis, Clinical Features and Treatment. Editor Kauffman H. Raven Press; 1991
  2. Wisniewski T.M., Wisniewski HM. Alzheimer’s Disease and the Cerebral Amyloidoses. In Neurodevelopment, Aging and Cognition. Editors Ivica Kostovic, Stevo Knezevic, Henry M. Wisniewski and George J. Spilich,  Birkhauser, Boston ; p157-172; 1992.
  3. Frangione B, Haltia M, Levy E, Ghiso J, Kiuru S, Prelli F, Wisniewski T. Familial amyloidosis- Finnish type- and its relationship to Lewy bodies in Parkinson’s and Diffuse Lewy Body disease. In the Proceedings of the XIth International Congress of Neuropathology- Kyoto; p150-156; 1992.
  4. Wisniewski T, Haltia M, Ghiso J, Frangione B.  I corpi di Lewy immunoreagisono con gli anticorpi dell-amiloide di tip Finnico omologo alla gelsolina.  Update on Parkinson’s disease and migraine 1992: 2:59-60.
  5. Wisniewski T, Frangione B. Aberrant aggregation of a normal amyloid precursor protein fragment. Neuroscience Facts 1992; 3:66.
  6. Frangione B, Wisniewski T, Tagliavini F, Bugiani O, Ghiso J. Alzheimer’s disease and Dutch variant: “Opposing faces of a single coin.” In Alzheimer’s Disease: Advances in Clinical and Basic Research. Editors:  Corain B, Iqbal K, Nicolin M. Wiley; p:387-396;1993.
  7. Frangione B, Wisniewski T, Ghiso J. Alzheimer’s disease and amyloid β. In Amyloid and Amyloidosis 1993. Ed.:Kiselevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID. Parthenon Publishing, 1994; pp:310-315.
  8. Ghiso J, Wisniewski T,  Frangione B.   Unifying features of systemic and cerebral amyloidoses.  Molecular Neurobiology 1994; 8: 49-64.
  9. Frangione B, Wisniewski T, Ghiso J. Position Paper on Alzheimer’s Disease Research. Neurobiology of Aging 1994; 15 (suppl  2):S97-S99.
  10. Frangione B, Wisniewski T, Castano E,  Ghiso J. Amyloids, Genes and Chaperones. In Research Advances in Alzheimer’s Disease and Related Disorders. Ed. Iqbal K., Mortimer JA, Winblad B, Wisniewski T. Publisher John Wiley, Chapter 61, pp:563-568; 1995.
  11. Zlokovic, B., Mackic, J., Martel, C., Wisniewski, T., Frangione, B., and Ghiso, J.:  The blood brain barrier regulates transport of Alzheimer’s amyloid β and apolipoproteins E and J.   In  K. Iqbal, J. Mortimer, B. Winblad and H. Wisniewski  (eds.)  Research advances in Alzheimer’s disease and related disorders.  Proceedings of the IV international conference on Alzheimer’s disease and related disorders.  Minneapolis, July/August, 1994.  John Wiley & Sons, Chichester (England), 1995, pp 585-595.
  12. Wisniewski T, Frangione B. The molecular biology of brain aging and neurodegenerative disorders. Acta Neurobiologiae Experimentalis 1996; 56: 267-279.
  13. Wisniewski T, Frangione B. Apolipoprotein E, Amyloidosis and Alzheimer’s Disease. Dementia (Japan) 1996; 10: 171-183.
  14. Frangione B, Castano EM, Wisniewski T, Ghiso J, Prelli F, Vidal R. Apolipoprotein E and amyloidosis. Ciba Foundation Symposium 1996; 199: 132-141.
  15. Frangione B, Castano EM, Prelli F, Soto C, Ghiso J, Wisniewski T. Chaperoning Amyloid in Alzheimer’s Disease: The Art of Avoiding Sticky Situations? In: A.D.Roses, K.H. Weisgraber and Y.Christen (ed.)  Apolipoprotein E and Alzheimer’s Disease; Springer-Verlag, Berlin, Heidelberg, 1996; pp:151-160.
  16. Wisniewski T, Ghiso J, Frangione B. Alzheimer’s Disease and Amyloid β. Neurobiology of Disease 1997; 4: 313-328.
  17. Wisniewski T, Dowjat K, Frangione B. The Prionoses and Other Conformational Disorders. Amyloid: The International Journal of Experimental and Clinical Investigation  1998; 5: 212-224.
  18. Wisniewski HM, Wegiel J, Wisniewski T. Pathogenesis of amyloid-ß plaques: activated microglia the cause of fibrillar amyloid formation and neuropil degeneration.     NeuroScience News 1998; 1: 30-34.
  19. Lalowski M, Baumann M, Rauvala H, Frangione B, Wisniewski T. HB-GAM, a novel amyloid associated protein, is present in prion related disorders and other cerebral amyloidoses. In: Fischer et al. (Editors) Progress in Alzheimer’s and Parkinson’s Diseases; Plenum Press, New York, 1998; pp: 121-131.
  20. Aucouturier, P, Frangione B, Wisniewski T. Prion Diseases and the Immune System. Annals of Internal Medicine (Paris, France), 1999; 150: 75-78.
  21. Wisniewski T, Frangione B. Amyloid: Chemical and Molecular Considerations. In: M. DeLeon (Ed.)  An Atlas of Alzheimer’s Disease. Parthenon Publishing, Carnforth, U.K., 1999; pp:109-130.
  22. Aucouturier P, Carp RI, Carnuad C, Wisniewski T. Prion Disease and the Immune System. Clinical Immunology, 2000, 96: 79-85.
  23. Wisniewski T, Frangione B. Book Review of Prion Biology and Diseases, Edited by Stanley B. Prusiner. New England Journal of Medicine, 2000, 342:983.
  24. Kayden HJ, Wisniewski T. On the biological activity of Vitamin E. American Journal of Clinical Nutrition, 2000, 72: 201-202.
  25. Wisniewski T. Henry M. Wisniewski, A life history. Journal of Alzheimer’s Disease, 2001, 3: 7-22.
  26. Wisniewski T, Sigurdsson EM, Aucouturier P, Frangione B. Chapter 13: Conformation as a Therapeutic Target in the Prionoses and other Neurodegenerative Conditions.   In  Baker HF  (ed.)  Molecular and Cellular Pathology in Prion Diseases.  The Humana Press, Inc.(Totowa, NJ) p: 223-236, 2001.
  27. Wisniewski T. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology., 2002
  28. Sigurdsson EM, Frangione B, Wisniewski T. A safer vaccine for Alzheimer’s disease?
    Neurobiology of Aging, 23: 1001-1008, 2002.
  29. Wisniewski T, Brown D, Sigurdsson EM. Therapeutics in Alzheimer’s and Prion Diseases. Biochemical Society Transactions, 30: 574-578, 2002.
  30. Sigurdsson EM, Frangione B, Wisniewski T. Immunization for Alzheimer’s Disease. Drug Development Research, 56: 135-142, 2002.
  31. Sigurdsson EM, Wisniewski T, Frangione B. Infectivity of Amyloid Diseases. Trends in Molecular Medicine, 8: 411-413, 2002.
  32. Wisniewski T, Sigurdsson EM. Immunization Treatment Approaches in Alzheimer and Prion Diseases. Current Neurology and Neuroscience Reports, 2: 400-404, 2002.
  33. Wegiel J, Wisniewski T, Reisberg B, Silverman W. Alzheimer dementia neuropathology. In: Dementia. Presentations, differential diagnosis, and nosology. Edited by V. Olga B. Emery, PhD. and Thomas E. Oxman, MD., The Johns Hopkins University Press, Baltimore and London, Chapter 4: 89-120, 2003.
  34. Sadowski M, Wisniewski T. Immunological treatment and imaging approaches for prion disease. Current Medical Chemistry: Immunology, Endocrine & Metabolic Agents, 3: 113-118, 2003.
  35. Sadowski M, Verma A, Wisniewski T. Prion Diseases. In Neurology in Clinical Practice, 4th Edition, Bradley W. (ed.), Chapter 59G: 1613-1630, 2004.
  36. Sigurdsson EM, Wadghiri YZ, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguilnaldo G, Duff K, Turnbull DH, Wisniewski T. In vivo magnetic resonance of amyloid plaques in Alzheimer’s disease model mice. Chapter in: The Living Brain and Alzheimer’s Disease, Fondation IPSEN. Pages: 47-59, Ed. Hyman B., Springer Verlag Berlin Heidelberg, 2004.
  37. Wisniewski T, Sadowski M. Book title: 100 Questions and Answers about Alzheimer’s disease. Jones and Bartlett Publishers, 2004.
  38. Sadowski M, Wisniewski T. Vaccines for Conformational Disorders. Expert Review of Vaccines, 3 (3): 279-290, 2004.
  39. Wisniewski T. Mad cow disease and variant Creutzfeldt-Jakob disease. In Lorenzo NY (ed.) eMedicine Neurology. , 2004.
  40. Ghiso J, Wisniewski T. An animal model of vascular amyloidosis. Nature Neuroscience, 7: 902-904, 2004.
  41. Sasson J, Sadowski M, Wisniewski T, Brown DR. Therapeutics and prion disease: can immunization or drugs be effective?  Mini-Reviews in Medicinal Chemistry, 5: 361-366, 2005.
  42. Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull DH.  MR Imaging of Amyloid Plaques in Transgenic Mice. Chapter 27, pages: 365-380; In Sigurdsson EM (ed) Amyloid Proteins: Methods in Molecular Biology Vol. 299, Humana Press Inc., Totowa, NJ, 2005.
  43. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathology, 15: 72-77, 2005.
  44. Wisniewski T. Is amyloid-beta-peptide immunization clinically effective in patients with Alzheimer's disease? Nature Clinical Practice Neurology. 1: 84-85, 2005.
  45. Sigurdsson E., Wisniewski T. Promising Developments in Prion Immunotherapy.      Expert Reviews of Vaccines, 4: 607-610, 2005. 
  46. Wisniewski T., Sigurdsson E. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology., 2006
  47. Sadowski M, Wisniewski T. Apolipoproteins in different amyloidoses. In Protein Misfolding. Aggregation and Conformational Diseases. Editors: Uversky VN, Fink AL; Kluwer Academic/Plenum Publishers. Chapter 16, pages: 329-350, 2006.
  48. Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Current Pharmaceutical Design 13(19):1943-54, 2007.
  49. Wisniewski T, Chabalgoity J.A. & Goni F. Is vaccination against transmissible spongiform encephalopathy feasible? In Animal vaccination – Part 1: development, production and use of vaccines (P.-P. Pastoret, M. Lombard & A.A. Schudel, eds). Rev. sci. tech. Off. int. Epiz., 26 (1), 243-251, 2007.
  50. Sigurdsson E., Wisniewski T. Therapeutic Approaches for Prion and Alzheimer's Diseases. FEBS Journal, 274: 3784-3798, 2007.
  51. Sadowski M, Verma A, Wisniewski T. Infections of the Nervous System: Prion Diseases. In Neurology in Clinical Practice, 5th Edition, Bradley W. (ed.), Chapter 57G, 1567-1581, 2008.
  52. Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurology, 7(9):805-811, 2008.
  53. Wisniewski T, Sadowski M. Preventing Aβ fibrillization and deposition: β-sheet        breakers and pathological chaperone inhibitors. BMC Neuroscience, 9(Suppl           2):S5, 2008.
  54. Wisniewski T. AD Vaccines: Conclusions and Future Directions, In CNS & Neurological Disorders-Drug Targets, 8(2): 160-166, 2009.
  55. Wisniewski T, Boutajangout A. Vaccination as a Therapeutic Approach for Alzheimer' Disease. Mount Sinai Journal of Medicine, 77: 17-31, 2010.
  56. Wisniewski T, Boutajangout A. Immunotherapeutic Approaches for Alzheimer's disease in transgenic mouse models. Brain Structure and Function, 214: 201-218, 2010.
  57. Wegiel J, Wisniewski T, Chauhan A, Chauhan V, Kuchna I, Nowicki K, Imaki H, Wegiel J, Ma SY, Bobrowicz T, Cohen I, London E, Brown TW. Type, topography, and sequelae of neuropathological changes: Shaping clinical phenotype of autism. In Autism: Oxidative stress, inflammation, and immune abnormalities. Boca Raton, FL, CRC Press, pages: 279-282, 2010.
  58. Wisniewski T, Sigurdsson EM. Murine Models of Alzheimer's Disease and Their Use in Developing Immunotherapies. BBA-Molecular Basis of Disease, 1802: 847-859, 2010.
  59. de Leon MJ, Rusinek H, Tsui W, Wisniewski T, Wegiel J, George A. Neuroimaging of cognitive disorders: commentary. Chapter 28 in Understanding Neuropsychiatric Disorders, Editors: Shenton ME, Turetsky BI. Cambridge University Press, pages: 395-401, 2010.
  60. Wisniewski T, Goni F. Immunomodulation for Prion and Prion Related Diseases. Expert       Review of Vaccines, 9(12): 1441-1452, 2010.
  61. Wadghiri YZ, Hoang DM, Wisniewski T, Sigurdsson EM. In vivo imaging of amyloid plaques in transgenic mice. Methods in Molecular Biology, 849: 435-451, 2012.
  62. Wisniewski, T, Goñi, F. Immunomodulation. In: Zou, W. Q., Gambetti, P. (Eds) Prions and Diseases, 1st ed., Volume 2: Animals, Humans and the Environment. Publisher: Springer, New York, Chapter 17: 267-287, 2012.
  63. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Davies P, Del Tredic K, Duychaerts C, Frosch MP, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer’s Disease Neuropathologic Changes and Cognitive Status: a Review of the Literature. Journal of Neuropathology and Experimental Neurology, 71(5):362-381, 2012.
  64. Wisniewski T, Goñi, F. Could Immunomodulation be used to Treat Prion Diseases? Expert Review of Anti-infective Therapy, 10(3): 307-317, 2012.
  65. Potter H, Wisniewski T. Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. International Journal of Alzheimer’s Disease, 2012:489428,  2012.
  66. Wisniewski T. Active Immunotherapy for Alzheimer’s disease. Lancet Neurology, 11(7):571-572, 2012.
  67. Wegiel J, Schanen NC, Cook EH, Brown WT, Kuchna I, Nowicki K, Wegiel J, Imaki H, Ma SY, London E, Wisniewski T. Clinicopathological stratification of idiopathic autism associated with duplications 15q11.2-q13.  In The Neuroscience of Autism Spectrum Disorders. Chapter 3.9, pages: 347-359, Edited by Joseph D. Buxbaum & Patrick R. Hof. Academic Press, Elsevier, Amsterdam, 2013
  68. Boutajangout A., Wisniewski T.  The Innate Immune System in Alzheimer’s Disease.
    International Journal of Cell Biology, Volume 2013, Article ID 576383, 1-7. 2013.
  69. Willhite CC, Karyakina NA, Yokel RA, Mornoli F, Yenugadhati N, Wisniewski TM, Ian MF, Krewski A, Krewski D. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanodot aluminum, aluminum oxide and the soluble salts. Critical Reviews in Toxicology, 44 (S4):1-80, 2014.
  70. Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T.  Down Syndrome and Alzheimer’s Disease: Common Pathways, Common Goals. Alzheimer's & Dementia, in press.
  71. Wegiel J, Morys J, Kowianski P, Ma SY, Kuchna I, Nowicki K, Imaki H, Wegiel J, Flory M, Brown TW, Wisniewski T. Delayed development of the claustrum in autism. In The Claustrum: Structural, Functional, and Clinical Neuroscience. Edited by Smythies JR, Edelstein LR, Ramachandran VS. Academic Press, Chapter 8, pages: 225-235, 2014.
  72. Wisniewski T, Goni F.  Immunotherapy for Alzheimer’s disease. Biochemical Pharmacology, 88: 499-507, 2014.
  73. Sabharwal P, Wisniewski T. Novel Immunological Approaches for the Treatment of Alzheimer’s disease, Chinese Journal of Contemporary Neurology and Neurosurgery, 14: 139-151, 2014.
  74. Boutajangout A, Wisniewski T. Tau as a therapeutic target in Alzheimer's disease. Gerontology, 60: 381-385, 2014.
  75. Yaghmoor F, Noorsaeed A, Alsaggaf S, Aljohami W, Scholtzova H, Boutajangout A, Wisniewski T. The Role of TREM2 in Alzheimer’s Disease and other Neurological Disorders. Journal of Alzheimer’s Disease and Parkinsonism, 4(5): 160, 2014.
  76. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Alafuzoff I, Arnold SE, Attems J, Beach TG, Cairns NJ, Dickson DW, Gearing M, Grinberg L, Hof PR, Hyman BT, Jellinger K, Kovacs GG, Knopman DS, Kofler J, Masliah E, McKee A, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White 3rd CL, Wisniewski T, Woltjer RL, Yamada M, and Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging.  Acta Neuropathologica, 128(6): 755-766. 2014.
  77. Rubenstein R, Peterson R, Wisniewski T. "Prion Diagnosis", In the Manual of Molecular and Clinical Laboratory Immunology (8th Edition) published by the American Society for Microbiology Press. (R.L. Hodinka, Ed.), in press.
  78. Wisniewski T, Goni F. Immunotherapeutic Approaches for Alzheimer’s Disease. Neuron, in press.

Total of 240 full length peer reviewed publications (161 peer reviewed original data manuscripts and 79 peer reviewed book chapters, reviews or books).
Average Citations per manuscript: ~20
H-Index: 58 (using Web of Science); 62 (using Google Scholar)

Total Citations: >13,000


Thomas Wisniewski



  • : 212-263-7993
  • : 212-263-7528

  • DEPARTMENTDepartment of Neurology, Pathology and Psychiatry
    New York University School of Medicine